JY
ORIC icon

Jeff Yass’s Oric Pharmaceuticals ORIC Stock Holding History

Jeff Yass’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.51M Buy
139,266
+116,211
+504% +$1.05M ﹤0.01% 7155
2026
Q1 		$292K Buy
+23,055
New +$262K ﹤0.01% 10916
2025
Q4 		– Sell
-16,348
Closed -$188K – 13240
2025
Q3 		$196K Sell
16,348
-124,652
-88% -$1.31M ﹤0.01% 11011
2025
Q2 		$1.43M Buy
141,000
+14,319
+11% +$96.1K ﹤0.01% 6569
2025
Q1 		$707K Buy
126,681
+95,619
+308% +$836K ﹤0.01% 8119
2024
Q4 		$251K Buy
31,062
+5,527
+22% +$50.7K ﹤0.01% 10207
2024
Q3 		$262K Sell
25,535
-8,510
-25% -$84.1K ﹤0.01% 9898
2024
Q2 		$241K Buy
+34,045
New +$305K ﹤0.01% 9948
2024
Q1 		– Sell
-54,389
Closed -$646K – 13014
2023
Q4 		$500K Buy
54,389
+44,300
+439% +$320K ﹤0.01% 8665
2023
Q3 		$61K Sell
10,089
-887
-8% -$7.27K ﹤0.01% 11204
2023
Q2 		$85.2K Sell
10,976
-227,462
-95% -$1.29M ﹤0.01% 11064
2023
Q1 		$1.36M Buy
238,438
+139,151
+140% +$727K ﹤0.01% 6041
2022
Q4 		$585K Buy
99,287
+79,310
+397% +$268K ﹤0.01% 7439
2022
Q3 		$64K Sell
19,977
-60,628
-75% -$243K ﹤0.01% 12045
2022
Q2 		$361K Buy
80,605
+48,533
+151% +$194K ﹤0.01% 9052
2022
Q1 		$171K Buy
32,072
+6,090
+23% +$54.8K ﹤0.01% 11425
2021
Q4 		$382K Buy
25,982
+8,916
+52% +$139K ﹤0.01% 9899
2021
Q3 		$357K Sell
17,066
-4,978
-23% -$101K ﹤0.01% 10200
2021
Q2 		$390K Sell
22,044
-21,312
-49% -$467K ﹤0.01% 10199
2021
Q1 		$1.06M Buy
+43,356
New +$1.37M ﹤0.01% 7581

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jeff Yass's ORIC Position: Q2 2026 in Review

Jeff Yass increased its Oric Pharmaceuticals (ORIC) stake by 504% in Q2 2026, buying an estimated $1.05M and bringing the position to 139,266 shares worth $1.51M. The position accounts for ﹤0.01% of the portfolio, ranked #7155.

Jeff Yass first reported a position in ORIC in Q1 2021 and has held it in 20 quarters since. 179 funds tracked by Wall St. Rank hold ORIC as of Q2 2026.

  • Jeff Yass held 139,266 shares of Oric Pharmaceuticals worth $1.51M as of Q2 2026.
  • Jeff Yass bought 116,211 Oric Pharmaceuticals shares in Q2 2026, an estimated $1.05M.
  • Oric Pharmaceuticals made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #7155 holding.
  • Jeff Yass first reported a position in Oric Pharmaceuticals in Q1 2021 and has held it in 20 quarters since.
  • 179 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.